SK3672000A3 - Method for the synthesis of quinoline derivatives - Google Patents

Method for the synthesis of quinoline derivatives Download PDF

Info

Publication number: SK3672000A3
Authority: SK; Slovakia
Prior art keywords: alkyl; formula; reaction mixture; compound; hydroxy
Prior art date: 1997-09-17

Application number

SK367-2000A

Other languages

English (en)

Slovak (sk)

Inventor

Joseph Sisko

Mark Mellinger

Conrad Kowalski

Original Assignee

Smithkline Beecham Corp

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1997-09-17

Filing date

1998-09-17

Publication date

2000-09-12

1998-09-17 Application filed by Smithkline Beecham Corp filed Critical Smithkline Beecham Corp

2000-09-12 Publication of SK3672000A3 publication Critical patent/SK3672000A3/sk

Links

238000000034 method Methods 0.000 title claims abstract description 52
125000002943 quinolinyl group Chemical class N1=C(C=CC2=CC=CC=C12)* 0.000 title claims description 8
229940027991 antiseptic and disinfectant quinoline derivative Drugs 0.000 title claims description 7
230000015572 biosynthetic process Effects 0.000 title description 14
238000003786 synthesis reaction Methods 0.000 title description 12
230000008569 process Effects 0.000 claims abstract description 24
BIAVGWDGIJKWRM-FQEVSTJZSA-N 3-hydroxy-2-phenyl-n-[(1s)-1-phenylpropyl]quinoline-4-carboxamide Chemical compound N([C@@H](CC)C=1C=CC=CC=1)C(=O)C(C1=CC=CC=C1N=1)=C(O)C=1C1=CC=CC=C1 BIAVGWDGIJKWRM-FQEVSTJZSA-N 0.000 claims abstract description 22
150000003248 quinolines Chemical class 0.000 claims abstract description 12
150000001875 compounds Chemical class 0.000 claims description 145
239000011541 reaction mixture Substances 0.000 claims description 110
125000000217 alkyl group Chemical group 0.000 claims description 89
229910052739 hydrogen Inorganic materials 0.000 claims description 53
239000001257 hydrogen Substances 0.000 claims description 53
125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 43
UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 33
229910052736 halogen Inorganic materials 0.000 claims description 33
150000002367 halogens Chemical class 0.000 claims description 33
125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 33
-1 C 1-6 -alkoxyalkyl Chemical group 0.000 claims description 31
239000002904 solvent Substances 0.000 claims description 30
ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 claims description 27
125000003118 aryl group Chemical group 0.000 claims description 27
125000003545 alkoxy group Chemical group 0.000 claims description 23
238000010438 heat treatment Methods 0.000 claims description 20
150000002431 hydrogen Chemical class 0.000 claims description 20
229910052760 oxygen Inorganic materials 0.000 claims description 20
FYSNRJHAOHDILO-UHFFFAOYSA-N thionyl chloride Chemical compound ClS(Cl)=O FYSNRJHAOHDILO-UHFFFAOYSA-N 0.000 claims description 19
125000005842 heteroatom Chemical group 0.000 claims description 18
125000001424 substituent group Chemical group 0.000 claims description 18
125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 claims description 17
229910052757 nitrogen Inorganic materials 0.000 claims description 17
230000003213 activating effect Effects 0.000 claims description 16
239000003795 chemical substances by application Substances 0.000 claims description 16
125000000623 heterocyclic group Chemical group 0.000 claims description 16
150000003839 salts Chemical class 0.000 claims description 16
238000002360 preparation method Methods 0.000 claims description 15
125000004442 acylamino group Chemical group 0.000 claims description 13
125000001544 thienyl group Chemical group 0.000 claims description 13
125000004454 (C1-C6) alkoxycarbonyl group Chemical group 0.000 claims description 12
229910052717 sulfur Inorganic materials 0.000 claims description 12
238000001816 cooling Methods 0.000 claims description 11
125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 11
125000006413 ring segment Chemical group 0.000 claims description 11
125000004916 (C1-C6) alkylcarbonyl group Chemical group 0.000 claims description 10
125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 10
238000004519 manufacturing process Methods 0.000 claims description 9
125000001624 naphthyl group Chemical group 0.000 claims description 9
125000004656 alkyl sulfonylamino group Chemical group 0.000 claims description 8
125000005518 carboxamido group Chemical group 0.000 claims description 8
125000000753 cycloalkyl group Chemical group 0.000 claims description 8
125000002541 furyl group Chemical group 0.000 claims description 8
125000002768 hydroxyalkyl group Chemical group 0.000 claims description 8
125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims description 8
XAPRFLSJBSXESP-UHFFFAOYSA-N oxycinchophen Chemical compound N=1C2=CC=CC=C2C(C(=O)O)=C(O)C=1C1=CC=CC=C1 XAPRFLSJBSXESP-UHFFFAOYSA-N 0.000 claims description 8
LMBFAGIMSUYTBN-MPZNNTNKSA-N teixobactin Chemical compound C([C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H](CCC(N)=O)C(=O)N[C@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H]1C(N[C@@H](C)C(=O)N[C@@H](C[C@@H]2NC(=N)NC2)C(=O)N[C@H](C(=O)O[C@H]1C)[C@@H](C)CC)=O)NC)C1=CC=CC=C1 LMBFAGIMSUYTBN-MPZNNTNKSA-N 0.000 claims description 8
125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims description 8
AQFLVLHRZFLDDV-VIFPVBQESA-N (1s)-1-phenylpropan-1-amine Chemical compound CC[C@H](N)C1=CC=CC=C1 AQFLVLHRZFLDDV-VIFPVBQESA-N 0.000 claims description 7
125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 7
125000001072 heteroaryl group Chemical group 0.000 claims description 7
125000005420 sulfonamido group Chemical group S(=O)(=O)(N*)* 0.000 claims description 7
125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 claims description 6
125000001725 pyrenyl group Chemical group 0.000 claims description 6
125000000335 thiazolyl group Chemical group 0.000 claims description 6
PMZKDGRAZFDNFC-BVMKMSJKSA-N C=1C=CC=CC=1C(CC)NC(=O)C([C@@]1(O)C=2N=C3C=CC=CC3=CC=2)(C(O)=O)C2=CC=CC=C2NC1(C=1C=CC=CC=1)C1=CC=CC=C1 Chemical compound C=1C=CC=CC=1C(CC)NC(=O)C([C@@]1(O)C=2N=C3C=CC=CC3=CC=2)(C(O)=O)C2=CC=CC=C2NC1(C=1C=CC=CC=1)C1=CC=CC=C1 PMZKDGRAZFDNFC-BVMKMSJKSA-N 0.000 claims description 5
125000002431 aminoalkoxy group Chemical group 0.000 claims description 5
125000001316 cycloalkyl alkyl group Chemical group 0.000 claims description 5
QCQCHGYLTSGIGX-GHXANHINSA-N 4-[[(3ar,5ar,5br,7ar,9s,11ar,11br,13as)-5a,5b,8,8,11a-pentamethyl-3a-[(5-methylpyridine-3-carbonyl)amino]-2-oxo-1-propan-2-yl-4,5,6,7,7a,9,10,11,11b,12,13,13a-dodecahydro-3h-cyclopenta[a]chrysen-9-yl]oxy]-2,2-dimethyl-4-oxobutanoic acid Chemical compound N([C@@]12CC[C@@]3(C)[C@]4(C)CC[C@H]5C(C)(C)[C@@H](OC(=O)CC(C)(C)C(O)=O)CC[C@]5(C)[C@H]4CC[C@@H]3C1=C(C(C2)=O)C(C)C)C(=O)C1=CN=CC(C)=C1 QCQCHGYLTSGIGX-GHXANHINSA-N 0.000 claims description 4
125000003107 substituted aryl group Chemical group 0.000 claims description 4
125000004448 alkyl carbonyl group Chemical group 0.000 claims description 3
125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims description 3
FZFIIACJTIBJMH-UHFFFAOYSA-N ethyl 3-acetyloxy-2-phenylquinoline-4-carboxylate Chemical compound N=1C2=CC=CC=C2C(C(=O)OCC)=C(OC(C)=O)C=1C1=CC=CC=C1 FZFIIACJTIBJMH-UHFFFAOYSA-N 0.000 claims description 3
GJVFBWCTGUSGDD-UHFFFAOYSA-L pentamethonium bromide Chemical compound [Br-].[Br-].C[N+](C)(C)CCCCC[N+](C)(C)C GJVFBWCTGUSGDD-UHFFFAOYSA-L 0.000 claims description 3
125000003342 alkenyl group Chemical group 0.000 claims description 2
125000003282 alkyl amino group Chemical group 0.000 claims description 2
125000004945 acylaminoalkyl group Chemical group 0.000 claims 1
125000004984 dialkylaminoalkoxy group Chemical group 0.000 claims 1
239000000543 intermediate Substances 0.000 abstract description 23
239000002585 base Substances 0.000 description 39
XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 24
WMFOQBRAJBCJND-UHFFFAOYSA-M Lithium hydroxide Chemical compound [Li+].[OH-] WMFOQBRAJBCJND-UHFFFAOYSA-M 0.000 description 24
238000006243 chemical reaction Methods 0.000 description 19
239000000047 product Substances 0.000 description 18
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 16
ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 15
150000001412 amines Chemical class 0.000 description 13
230000008878 coupling Effects 0.000 description 13
238000010168 coupling process Methods 0.000 description 13
238000005859 coupling reaction Methods 0.000 description 13
WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 12
HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 12
JXDYKVIHCLTXOP-UHFFFAOYSA-N isatin Chemical compound C1=CC=C2C(=O)C(=O)NC2=C1 JXDYKVIHCLTXOP-UHFFFAOYSA-N 0.000 description 11
IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 10
KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 9
YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 9
229940061720 alpha hydroxy acid Drugs 0.000 description 8
150000001280 alpha hydroxy acids Chemical class 0.000 description 8
SMWDFEZZVXVKRB-UHFFFAOYSA-N Quinoline Chemical compound N1=CC=CC2=CC=CC=C21 SMWDFEZZVXVKRB-UHFFFAOYSA-N 0.000 description 6
125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 6
BZLVMXJERCGZMT-UHFFFAOYSA-N Methyl tert-butyl ether Chemical compound COC(C)(C)C BZLVMXJERCGZMT-UHFFFAOYSA-N 0.000 description 5
102000002003 Neurokinin-3 Receptors Human genes 0.000 description 5
108010040716 Neurokinin-3 Receptors Proteins 0.000 description 5
125000004432 carbon atom Chemical group C* 0.000 description 5
238000004587 chromatography analysis Methods 0.000 description 5
239000012458 free base Substances 0.000 description 5
125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 5
239000002464 receptor antagonist Substances 0.000 description 5
229940044551 receptor antagonist Drugs 0.000 description 5
239000000725 suspension Substances 0.000 description 5
150000003512 tertiary amines Chemical class 0.000 description 5
JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 4
WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 4
239000002253 acid Substances 0.000 description 4
239000006227 byproduct Substances 0.000 description 4
239000000203 mixture Substances 0.000 description 4
125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 4
CTSLXHKWHWQRSH-UHFFFAOYSA-N oxalyl chloride Chemical compound ClC(=O)C(Cl)=O CTSLXHKWHWQRSH-UHFFFAOYSA-N 0.000 description 4
125000004076 pyridyl group Chemical group 0.000 description 4
239000007787 solid Substances 0.000 description 4
BHCSUEHQURQVLD-BDQAORGHSA-N 3-hydroxy-2-phenyl-n-[(1s)-1-phenylpropyl]quinoline-4-carboxamide;hydrochloride Chemical compound Cl.N([C@@H](CC)C=1C=CC=CC=1)C(=O)C(C1=CC=CC=C1N=1)=C(O)C=1C1=CC=CC=C1 BHCSUEHQURQVLD-BDQAORGHSA-N 0.000 description 3
QOSSAOTZNIDXMA-UHFFFAOYSA-N Dicylcohexylcarbodiimide Chemical compound C1CCCCC1N=C=NC1CCCCC1 QOSSAOTZNIDXMA-UHFFFAOYSA-N 0.000 description 3
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 3
150000001298 alcohols Chemical class 0.000 description 3
RQPZNWPYLFFXCP-UHFFFAOYSA-L barium dihydroxide Chemical compound [OH-].[OH-].[Ba+2] RQPZNWPYLFFXCP-UHFFFAOYSA-L 0.000 description 3
229910001863 barium hydroxide Inorganic materials 0.000 description 3
AXCZMVOFGPJBDE-UHFFFAOYSA-L calcium dihydroxide Chemical compound [OH-].[OH-].[Ca+2] AXCZMVOFGPJBDE-UHFFFAOYSA-L 0.000 description 3
239000000920 calcium hydroxide Substances 0.000 description 3
229910001861 calcium hydroxide Inorganic materials 0.000 description 3
KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
125000003678 cyclohexadienyl group Chemical group C1(=CC=CCC1)* 0.000 description 3
UAOMVDZJSHZZME-UHFFFAOYSA-N diisopropylamine Chemical compound CC(C)NC(C)C UAOMVDZJSHZZME-UHFFFAOYSA-N 0.000 description 3
239000012065 filter cake Substances 0.000 description 3
125000005843 halogen group Chemical group 0.000 description 3
229910052740 iodine Inorganic materials 0.000 description 3
RLOWWWKZYUNIDI-UHFFFAOYSA-N phosphinic chloride Chemical compound ClP=O RLOWWWKZYUNIDI-UHFFFAOYSA-N 0.000 description 3
150000003335 secondary amines Chemical class 0.000 description 3
239000007858 starting material Substances 0.000 description 3
125000006272 (C3-C7) cycloalkyl group Chemical group 0.000 description 2
YRNDGUSDBCARGC-UHFFFAOYSA-N 2-methoxyacetophenone Chemical compound COCC(=O)C1=CC=CC=C1 YRNDGUSDBCARGC-UHFFFAOYSA-N 0.000 description 2
WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 2
IAZDPXIOMUYVGZ-WFGJKAKNSA-N Dimethyl sulfoxide Chemical compound [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 2
PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 2
208000019693 Lung disease Diseases 0.000 description 2
DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 2
206010046543 Urinary incontinence Diseases 0.000 description 2
150000001242 acetic acid derivatives Chemical class 0.000 description 2
125000004457 alkyl amino carbonyl group Chemical group 0.000 description 2
150000001408 amides Chemical class 0.000 description 2
239000005557 antagonist Substances 0.000 description 2
239000000010 aprotic solvent Substances 0.000 description 2
GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 2
229910052794 bromium Inorganic materials 0.000 description 2
239000003153 chemical reaction reagent Substances 0.000 description 2
239000000460 chlorine Substances 0.000 description 2
125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 2
239000008367 deionised water Substances 0.000 description 2
229910021641 deionized water Inorganic materials 0.000 description 2
238000001514 detection method Methods 0.000 description 2
239000011737 fluorine Substances 0.000 description 2
229910052731 fluorine Inorganic materials 0.000 description 2
238000004128 high performance liquid chromatography Methods 0.000 description 2
125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 2
230000007246 mechanism Effects 0.000 description 2
125000001160 methoxycarbonyl group Chemical group [H]C([H])([H])OC(*)=O 0.000 description 2
VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 2
BGAXCPSNMHVHJC-UHFFFAOYSA-N phenacyl acetate Chemical compound CC(=O)OCC(=O)C1=CC=CC=C1 BGAXCPSNMHVHJC-UHFFFAOYSA-N 0.000 description 2
ISWSIDIOOBJBQZ-UHFFFAOYSA-N phenol group Chemical group C1(=CC=CC=C1)O ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 2
239000003495 polar organic solvent Substances 0.000 description 2
SCVFZCLFOSHCOH-UHFFFAOYSA-M potassium acetate Chemical compound [K+].CC([O-])=O SCVFZCLFOSHCOH-UHFFFAOYSA-M 0.000 description 2
238000000746 purification Methods 0.000 description 2
239000013557 residual solvent Substances 0.000 description 2
238000001228 spectrum Methods 0.000 description 2
238000010189 synthetic method Methods 0.000 description 2
YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 2
238000005292 vacuum distillation Methods 0.000 description 2
XTFIVUDBNACUBN-UHFFFAOYSA-N 1,3,5-trinitro-1,3,5-triazinane Chemical compound [O-][N+](=O)N1CN([N+]([O-])=O)CN([N+]([O-])=O)C1 XTFIVUDBNACUBN-UHFFFAOYSA-N 0.000 description 1
125000004214 1-pyrrolidinyl group Chemical group [H]C1([H])N(*)C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
125000004182 2-chlorophenyl group Chemical group [H]C1=C([H])C(Cl)=C(*)C([H])=C1[H] 0.000 description 1
125000000175 2-thienyl group Chemical group S1C([*])=C([H])C([H])=C1[H] 0.000 description 1
MXNVEJDRXSFZQB-UHFFFAOYSA-N 3-hydroxyquinoline-4-carboxylic acid Chemical class C1=CC=C2C(C(=O)O)=C(O)C=NC2=C1 MXNVEJDRXSFZQB-UHFFFAOYSA-N 0.000 description 1
ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 1
QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical group CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 1
208000024827 Alzheimer disease Diseases 0.000 description 1
208000019901 Anxiety disease Diseases 0.000 description 1
JVYMKTAPCLSXLC-UHFFFAOYSA-N COClO Chemical compound COClO JVYMKTAPCLSXLC-UHFFFAOYSA-N 0.000 description 1
OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
101150015280 Cel gene Proteins 0.000 description 1
ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
206010010904 Convulsion Diseases 0.000 description 1
206010011224 Cough Diseases 0.000 description 1
206010012438 Dermatitis atopic Diseases 0.000 description 1
208000030814 Eating disease Diseases 0.000 description 1
206010015150 Erythema Diseases 0.000 description 1
206010015943 Eye inflammation Diseases 0.000 description 1
208000019454 Feeding and Eating disease Diseases 0.000 description 1
238000010268 HPLC based assay Methods 0.000 description 1
208000023105 Huntington disease Diseases 0.000 description 1
206010065390 Inflammatory pain Diseases 0.000 description 1
241000124008 Mammalia Species 0.000 description 1
208000023178 Musculoskeletal disease Diseases 0.000 description 1
208000007920 Neurogenic Inflammation Diseases 0.000 description 1
208000018737 Parkinson disease Diseases 0.000 description 1
YGYAWVDWMABLBF-UHFFFAOYSA-N Phosgene Chemical compound ClC(Cl)=O YGYAWVDWMABLBF-UHFFFAOYSA-N 0.000 description 1
208000003251 Pruritus Diseases 0.000 description 1
201000004681 Psoriasis Diseases 0.000 description 1
206010039085 Rhinitis allergic Diseases 0.000 description 1
VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
206010058679 Skin oedema Diseases 0.000 description 1
125000003668 acetyloxy group Chemical group [H]C([H])([H])C(=O)O[*] 0.000 description 1
150000007513 acids Chemical class 0.000 description 1
125000004183 alkoxy alkyl group Chemical group 0.000 description 1
125000004453 alkoxycarbonyl group Chemical group 0.000 description 1
125000000278 alkyl amino alkyl group Chemical group 0.000 description 1
150000001347 alkyl bromides Chemical class 0.000 description 1
201000010105 allergic rhinitis Diseases 0.000 description 1
ZXKINMCYCKHYFR-UHFFFAOYSA-N aminooxidanide Chemical compound [O-]N ZXKINMCYCKHYFR-UHFFFAOYSA-N 0.000 description 1
230000036506 anxiety Effects 0.000 description 1
208000006673 asthma Diseases 0.000 description 1
QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
201000008937 atopic dermatitis Diseases 0.000 description 1
230000008901 benefit Effects 0.000 description 1
125000004618 benzofuryl group Chemical group O1C(=CC2=C1C=CC=C2)* 0.000 description 1
239000004305 biphenyl Substances 0.000 description 1
229910052799 carbon Inorganic materials 0.000 description 1
208000015114 central nervous system disease Diseases 0.000 description 1
238000004296 chiral HPLC Methods 0.000 description 1
229910052801 chlorine Inorganic materials 0.000 description 1
230000001684 chronic effect Effects 0.000 description 1
125000004122 cyclic group Chemical group 0.000 description 1
125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 1
150000004985 diamines Chemical class 0.000 description 1
229940043279 diisopropylamine Drugs 0.000 description 1
235000014632 disordered eating Nutrition 0.000 description 1
238000001035 drying Methods 0.000 description 1
235000005686 eating Nutrition 0.000 description 1
206010015037 epilepsy Diseases 0.000 description 1
239000012467 final product Substances 0.000 description 1
125000003187 heptyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
208000013403 hyperactivity Diseases 0.000 description 1
238000011065 in-situ storage Methods 0.000 description 1
230000005764 inhibitory process Effects 0.000 description 1
239000011630 iodine Substances 0.000 description 1
125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
238000002955 isolation Methods 0.000 description 1
JJWLVOIRVHMVIS-UHFFFAOYSA-N isopropylamine Chemical compound CC(C)N JJWLVOIRVHMVIS-UHFFFAOYSA-N 0.000 description 1
230000007803 itching Effects 0.000 description 1
208000017169 kidney disease Diseases 0.000 description 1
201000006370 kidney failure Diseases 0.000 description 1
238000004811 liquid chromatography Methods 0.000 description 1
239000000463 material Substances 0.000 description 1
230000001404 mediated effect Effects 0.000 description 1
238000002844 melting Methods 0.000 description 1
230000008018 melting Effects 0.000 description 1
125000004458 methylaminocarbonyl group Chemical group [H]N(C(*)=O)C([H])([H])[H] 0.000 description 1
125000004674 methylcarbonyl group Chemical group CC(=O)* 0.000 description 1
238000012986 modification Methods 0.000 description 1
230000004048 modification Effects 0.000 description 1
208000015122 neurodegenerative disease Diseases 0.000 description 1
238000001208 nuclear magnetic resonance pulse sequence Methods 0.000 description 1
230000000414 obstructive effect Effects 0.000 description 1
239000012074 organic phase Substances 0.000 description 1
239000001301 oxygen Substances 0.000 description 1
125000004430 oxygen atom Chemical group O* 0.000 description 1
239000012071 phase Substances 0.000 description 1
235000011056 potassium acetate Nutrition 0.000 description 1
230000003389 potentiating effect Effects 0.000 description 1
239000002244 precipitate Substances 0.000 description 1
230000001376 precipitating effect Effects 0.000 description 1
VQMSRUREDGBWKT-UHFFFAOYSA-N quinoline-4-carboxylic acid Chemical class C1=CC=C2C(C(=O)O)=CC=NC2=C1 VQMSRUREDGBWKT-UHFFFAOYSA-N 0.000 description 1
125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
238000000926 separation method Methods 0.000 description 1
208000017520 skin disease Diseases 0.000 description 1
230000003595 spectral effect Effects 0.000 description 1
LSNNMFCWUKXFEE-UHFFFAOYSA-L sulfite Chemical class [O-]S([O-])=O LSNNMFCWUKXFEE-UHFFFAOYSA-L 0.000 description 1
208000024891 symptom Diseases 0.000 description 1
125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
230000001225 therapeutic effect Effects 0.000 description 1
125000004305 thiazinyl group Chemical group S1NC(=CC=C1)* 0.000 description 1
238000004809 thin layer chromatography Methods 0.000 description 1
239000003440 toxic substance Substances 0.000 description 1
239000013638 trimer Substances 0.000 description 1
238000003828 vacuum filtration Methods 0.000 description 1
231100000925 very toxic Toxicity 0.000 description 1
238000005406 washing Methods 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/20—Oxygen atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/36—Sulfur atoms
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
- C07D209/32—Oxygen atoms
- C07D209/38—Oxygen atoms in positions 2 and 3, e.g. isatin
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/38—Nitrogen atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
- C07D215/50—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 4
- C07D215/52—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 4 with aryl radicals attached in position 2

Landscapes

Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Health & Medical Sciences (AREA)
Pulmonology (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Plural Heterocyclic Compounds (AREA)
Quinoline Compounds (AREA)
Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)

SK367-2000A 1997-09-17 1998-09-17 Method for the synthesis of quinoline derivatives SK3672000A3 (en)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US5930397P	1997-09-17	1997-09-17
PCT/US1998/019434 WO1999014196A1 (en)	1997-09-17	1998-09-17	Method for the synthesis of quinoline derivatives

Publications (1)

Publication Number	Publication Date
SK3672000A3 true SK3672000A3 (en)	2000-09-12

Family

ID=22022126

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
SK367-2000A SK3672000A3 (en)	1997-09-17	1998-09-17	Method for the synthesis of quinoline derivatives

Country Status (32)

Country	Link
US (6)	US6335448B1 (xx)
EP (1)	EP1017676B1 (xx)
JP (1)	JP2001516744A (xx)
KR (1)	KR20010024031A (xx)
CN (1)	CN1125815C (xx)
AP (1)	AP1201A (xx)
AR (1)	AR015445A1 (xx)
AT (1)	ATE353879T1 (xx)
AU (1)	AU744538B2 (xx)
BG (1)	BG104243A (xx)
BR (1)	BR9812085A (xx)
CA (1)	CA2303026A1 (xx)
DE (1)	DE69837100T2 (xx)
DZ (1)	DZ2607A1 (xx)
EA (1)	EA002633B1 (xx)
ES (1)	ES2283072T3 (xx)
HU (1)	HUP0004855A3 (xx)
ID (1)	ID24140A (xx)
IL (1)	IL134991A0 (xx)
MA (1)	MA24644A1 (xx)
MY (1)	MY120237A (xx)
NO (1)	NO314303B1 (xx)
NZ (1)	NZ503307A (xx)
OA (1)	OA11340A (xx)
PE (1)	PE129299A1 (xx)
PL (1)	PL339340A1 (xx)
SK (1)	SK3672000A3 (xx)
TR (1)	TR200000720T2 (xx)
TW (1)	TW509678B (xx)
UY (2)	UY25174A1 (xx)
WO (1)	WO1999014196A1 (xx)
ZA (1)	ZA988455B (xx)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
AP1201A (en) *	1997-09-17	2003-09-01	Smithkline Beecham Corp	Method for the synthesis of quinoline derivatives.
JP2002540203A (ja)	1999-03-29	2002-11-26	ニューロゲンコーポレイション	Ｎｋ−３および／またはｇａｂａ（ａ）受容体リガンドとしての４−置換キノリン誘導体
JP2007520543A (ja)	2004-02-04	2007-07-26	ファイザー・プロダクツ・インク	置換キノリン化合物
CA2611060A1 (en) *	2005-06-03	2006-12-07	R. Thomas Simpson	Quinoline derivatives as nk3 antagonists
WO2007016609A2 (en) *	2005-08-02	2007-02-08	Smithkline Beecham Corporation	Method for the synthesis of quinoliνe derivatives
WO2007018469A1 (en) *	2005-08-11	2007-02-15	Astrazeneca Ab	Oxopyridyl quinoline amides as nk3 receptor modulators
WO2007035156A1 (en) *	2005-09-21	2007-03-29	Astrazeneca Ab	N-oxo-heterocycle and n-oxo-alkyl quinoline-4-carboxamides as nk-3 receptor ligands
AR057130A1 (es) *	2005-09-21	2007-11-14	Astrazeneca Ab	Quinolinas de alquilsulfoxido y una composicion farmaceutica
EP1981882A4 (en) *	2006-01-27	2009-11-18	Astrazeneca Ab	QUINOLINES SUBSTITUTED BY AN AMIDE
CN102924375B (zh) *	2012-06-21	2015-02-18	江苏恩华药业股份有限公司	Talnetant中间体及其制备方法和应用
CN102702099A (zh) *	2012-06-21	2012-10-03	江苏恩华药业股份有限公司	(s)-3-羟基-2-苯基-n-(1-苯基丙基)喹啉-4-甲酰胺的制备方法
CN103214416A (zh) *	2013-04-26	2013-07-24	扬州大学	一种合成多取代喹啉类化合物的方法

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US2776290A (en) *		1957-01-01		Hydroxy cevchoninates and carboxylic
KR100316571B1 (ko) *	1994-05-27	2002-05-30	파올로 비지, 엔리꼬 카쭐라니	타키키닌nk3수용체길항제로서퀴놀린유도체
US5627193A (en) *	1995-02-09	1997-05-06	Mitsui Toatsu Chemicals, Inc.	Quinoline-4-carbonylguanidine derivatives, process for producing the same and pharmaceutical preparations containing the compounds
AP1201A (en) *	1997-09-17	2003-09-01	Smithkline Beecham Corp	Method for the synthesis of quinoline derivatives.

1998
- 1998-05-08 AP APAP/P/2000/001767A patent/AP1201A/en active
- 1998-09-08 UY UY25174A patent/UY25174A1/es not_active Application Discontinuation
- 1998-09-08 MA MA25246A patent/MA24644A1/fr unknown
- 1998-09-11 PE PE1998000868A patent/PE129299A1/es not_active Application Discontinuation
- 1998-09-14 DZ DZ980217A patent/DZ2607A1/xx active
- 1998-09-15 MY MYPI98004207A patent/MY120237A/en unknown
- 1998-09-16 ZA ZA988455A patent/ZA988455B/xx unknown
- 1998-09-16 AR ARP980104603A patent/AR015445A1/es not_active Application Discontinuation
- 1998-09-17 IL IL13499198A patent/IL134991A0/xx unknown
- 1998-09-17 SK SK367-2000A patent/SK3672000A3/sk unknown
- 1998-09-17 EP EP98947099A patent/EP1017676B1/en not_active Expired - Lifetime
- 1998-09-17 WO PCT/US1998/019434 patent/WO1999014196A1/en active IP Right Grant
- 1998-09-17 HU HU0004855A patent/HUP0004855A3/hu unknown
- 1998-09-17 JP JP2000511747A patent/JP2001516744A/ja active Pending
- 1998-09-17 US US09/508,358 patent/US6335448B1/en not_active Expired - Fee Related
- 1998-09-17 AT AT98947099T patent/ATE353879T1/de not_active IP Right Cessation
- 1998-09-17 NZ NZ503307A patent/NZ503307A/en unknown
- 1998-09-17 TR TR2000/00720T patent/TR200000720T2/xx unknown
- 1998-09-17 KR KR1020007002766A patent/KR20010024031A/ko not_active Ceased
- 1998-09-17 CA CA002303026A patent/CA2303026A1/en not_active Abandoned
- 1998-09-17 DE DE69837100T patent/DE69837100T2/de not_active Expired - Lifetime
- 1998-09-17 AU AU93958/98A patent/AU744538B2/en not_active Ceased
- 1998-09-17 PL PL98339340A patent/PL339340A1/xx unknown
- 1998-09-17 ID IDW20000498A patent/ID24140A/id unknown
- 1998-09-17 ES ES98947099T patent/ES2283072T3/es not_active Expired - Lifetime
- 1998-09-17 CN CN98810978A patent/CN1125815C/zh not_active Expired - Fee Related
- 1998-09-17 EA EA200000322A patent/EA002633B1/ru not_active IP Right Cessation
- 1998-09-17 BR BR9812085-9A patent/BR9812085A/pt not_active IP Right Cessation
- 1998-09-29 TW TW087114858A patent/TW509678B/zh not_active IP Right Cessation
1999
- 1999-02-26 UY UY25407A patent/UY25407A1/es unknown
2000
- 2000-03-15 BG BG104243A patent/BG104243A/xx unknown
- 2000-03-16 NO NO20001387A patent/NO314303B1/no not_active IP Right Cessation
- 2000-03-16 OA OA1200000078A patent/OA11340A/en unknown
2001
- 2001-10-17 US US09/981,185 patent/US20020038029A1/en not_active Abandoned
2002
- 2002-06-17 US US10/174,458 patent/US20020173657A1/en not_active Abandoned
2003
- 2003-05-20 US US10/441,708 patent/US20040049031A1/en not_active Abandoned
2005
- 2005-03-30 US US11/093,701 patent/US20050171152A1/en not_active Abandoned
2006
- 2006-04-28 US US11/413,932 patent/US20060189809A1/en not_active Abandoned

Also Published As

Publication number	Publication date
US6335448B1 (en)	2002-01-01
HUP0004855A3 (en)	2001-08-28
BG104243A (en)	2001-05-31
DE69837100T2 (de)	2007-11-22
CN1125815C (zh)	2003-10-29
NO20001387D0 (no)	2000-03-16
MA24644A1 (fr)	1999-04-01
EA002633B1 (ru)	2002-08-29
US20050171152A1 (en)	2005-08-04
US20020038029A1 (en)	2002-03-28
CN1278796A (zh)	2001-01-03
IL134991A0 (en)	2001-05-20
NO314303B1 (no)	2003-03-03
TW509678B (en)	2002-11-11
UY25407A1 (es)	1999-11-17
EP1017676A1 (en)	2000-07-12
JP2001516744A (ja)	2001-10-02
DE69837100D1 (de)	2007-03-29
US20020173657A1 (en)	2002-11-21
UY25174A1 (es)	2001-07-31
AP1201A (en)	2003-09-01
ES2283072T3 (es)	2007-10-16
PL339340A1 (en)	2000-12-18
EA200000322A1 (ru)	2000-10-30
OA11340A (en)	2003-12-09
ZA988455B (en)	1999-02-17
WO1999014196A1 (en)	1999-03-25
PE129299A1 (es)	2000-02-19
ATE353879T1 (de)	2007-03-15
KR20010024031A (ko)	2001-03-26
DZ2607A1 (fr)	2003-03-01
EP1017676B1 (en)	2007-02-14
AU744538B2 (en)	2002-02-28
US20040049031A1 (en)	2004-03-11
AR015445A1 (es)	2001-05-02
ID24140A (id)	2000-07-06
BR9812085A (pt)	2000-09-26
TR200000720T2 (tr)	2000-08-21
HUP0004855A2 (hu)	2001-06-28
EP1017676A4 (en)	2002-12-04
NZ503307A (en)	2002-04-26
NO20001387L (no)	2000-03-16
CA2303026A1 (en)	1999-03-25
AP2000001767A0 (en)	2000-03-31
AU9395898A (en)	1999-04-05
MY120237A (en)	2005-09-30
US20060189809A1 (en)	2006-08-24

Publication	Publication Date	Title
US20060189809A1 (en)	2006-08-24	Method for the synthesis of quinoline derivatives
FR2614620A1 (fr)	1988-11-04	Derives de la 1,4-dihydro-4-oxonaphtyridine et leurs sels, procede pour leur production et agents anti-bacteriens les contenant
AU2009305477B2 (en)	2014-04-17	Process for the preparation of optically active (S)-(-)-2- (N-propylamino)-5-methoxytetraline and (S)-(-)-2- (N-propylamino)-5-hydroxytetraline compounds
US9533971B2 (en)	2017-01-03	Process for the synthesis of dabigatran and its intermediates
WO2017119666A1 (ko)	2017-07-13	극성 비양자성 용매를 이용한 n-[4-(1-아미노에틸)-페닐]-술폰아미드 유도체의 카이랄 분할 방법
US20080194623A1 (en)	2008-08-14	Method for the Synthesis of Quinoline Derivatives
KR100228328B1 (ko)	1999-11-01	(2r)-메틸-4,4,4-트리플루오로부틸아민 또는 이것의 산부가염을 제조하는 방법
CZ2000922A3 (cs)	2000-09-13	Způsob syntézy chinolinových derivátů
EP1652840A2 (en)	2006-05-03	(-)-(S)-N-(.alpha.-ethylbenzyl)-3-hydroxy-2-phenylquinoline-4-carboxamide
CA2367971A1 (en)	2000-09-28	Synthesis of 3-amino-3-aryl propanoates
MXPA00002695A (en)	2002-03-26	Method for the synthesis of quinoline derivatives
JPH0525162A (ja)	1993-02-02	キノロン誘導体およびその製造法
AU1020902A (en)	2002-03-14	Method for the synthesis of quinoline derivatives
EP3292102B1 (en)	2021-09-08	Isoindolinones, processes for the production of chiral derivatives thereof and use thereof
WO1996004246A1 (en)	1996-02-15	Phenylacetamides having leukotriene-antagonistic action
FR2632305A1 (fr)	1989-12-08	Amino-4 aroyl-3 quinoleines et naphtyridines, leur procede de preparation et leur application en therapeutique
ITMI972354A1 (it)	1999-04-17	Derivati chinolinici procedimento per la loro preparazione e uso come antagonisti del recettore nk3
ITMI952461A1 (it)	1997-05-24	Derivati chinolinici
ITMI952460A1 (it)	1997-05-24	Derivati chinolinici
ITMI972352A1 (it)	1999-04-17	Derivati chinolinici, procedimento per la loro preparazione e uso come antagonisti del recettore nk3
ITMI972775A1 (it)	1999-06-16	Derivati chinolinici procedimento per la loro preparazione e uso come antagonisti del recettore nk3